LANREOTIDE

lanreotide 120 mg/0.5 mL injection, 0.5 mL syringe

LANREOTIDE (11736Q)

lanreotide 120 mg/0.5 mL injection, 0.5 mL syringe
11736Q
Body System:
Manner of administration:Injection
S100 HSD Community Access
Authority Required (STREAMLINED)

Restriction  17638

Indication: Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)
Treatment phase: Initial treatment

Restriction  17696

Indication: Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 2 Max qty units: 2 # of repeats: 5 DPMQ: $2,630.40 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Mytolac
Somatuline Autogel